Gene test may cut chemo harm in pancreatic and colon cancer
NCT ID NCT05391126
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether using a person's genetic information to guide chemotherapy dosing can lower the risk of severe side effects. About 178 adults with colorectal or pancreatic cancer will be randomly assigned to either standard dosing or dosing based on their UGT1A1 gene type. The main goal is to see if the gene-guided approach reduces serious side effects during the first treatment cycle.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Kentucky
RECRUITINGLexington, Kentucky, 40506, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••